𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Non-hopfian groups with fully invariant kernels. II

✍ Scribed by Michael Anshel

Publisher
Elsevier Science
Year
1973
Tongue
English
Weight
461 KB
Volume
24
Category
Article
ISSN
0021-8693

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8552
✍ Case, Delvyn C. ;Anderson, James ;Ervin, Thomas J. ;Gottlieb, Arlan πŸ“‚ Article πŸ“… 1988 πŸ› John Wiley and Sons 🌐 English βš– 481 KB

Ifosfamide (1.25 g/m2 intravenously/day x 5) with mesna (20% of the ifosfamide dose x six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non-Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29% response rate (9/31) was observed (2 CR and

Phase II trial of ifosfamide and mesna i
Phase II trial of ifosfamide and mesna in previously treated patients with non-hodgkin's lymphoma: Cancer and leukemia group b study 8552
✍ Delvyn C. Case JR; James Anderson; Thomas J. Ervin; Arlan Gottlieb πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 522 KB

## Abstract Ifosfamide (1Β·25 g/m^2^ intravenously/day Γ— 5) with mesna (20 per cent of the ifosfamide dose Γ— six doses on each day of ifosfamide therapy) was administered to 46 previously treated patients with non‐Hodgkin's lymphoma of which 31 were eligible and evaluable. A 29 per cent response rat

Phase II trial of ifosfamide/mesna and m
Phase II trial of ifosfamide/mesna and mitoxantrone in previously treated patients with non-Hodgkin's lymphoma: Cancer and leukemia group B study 8753
✍ Case, Delvyn C. ;Santarelli, Maria Teresa ;Carey, Robert W. ;Anderson, James ;Go πŸ“‚ Article πŸ“… 1992 πŸ› John Wiley and Sons 🌐 English βš– 461 KB

## Abstract Ifosfamide (2.0 g/m^2^ intravenously/day Γ— 3) with mesna (400 mg/m^2^ intravenously q 4 h daily Γ— 3) was combined with mitoxantrone (14 mg/m^2^ intravenously Γ— 1) and given on a 3 week schedule to patients with previously treated non‐Hodkgin's lymphoma. In 45 eligible/evaluable patients

Phase II trial of etoposide and cisplati
Phase II trial of etoposide and cisplatin in patients with refractory and relapsed non-Hodgkin's lymphoma: Cancer and leukemia group B study 8351
✍ Rybak, Mary Ellen ;Anderson, James ;Kaplan, Richard ;Budman, Daniel R. ;Vincigue πŸ“‚ Article πŸ“… 1993 πŸ› John Wiley and Sons 🌐 English βš– 435 KB

## Abstract A phase‐II study was conducted by the Cancer and Leukemia Group B (CALGB) in patients with refractory and relapsed non‐Hodgkin's lymphoma (NHL) to assess the activity of the combination of etoposide and cisplatin. Sixty‐five patients were entered on study, and 51 patients were evaluated